BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31365753)

  • 1. Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.
    Jabbour E
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365753
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric Acute Lymphoblastic Leukemia.
    Rheingold SR
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
    Liu D; Zhao J; Song Y; Luo X; Yang T
    J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
    Perica K; Flynn J; Curran KJ; Rivere I; Wang X; Senechal B; Halton E; Diamonte C; Pineda J; Bernal Y; Gonen M; Sadelain M; Brentjens RJ; Park JH
    Leukemia; 2021 Nov; 35(11):3268-3271. PubMed ID: 33686196
    [No Abstract]   [Full Text] [Related]  

  • 6. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
    Aldoss I; Forman SJ
    Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
    Paul S; Rausch CR; Kantarjian H; Jabbour EJ
    Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
    Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
    Wang Y; Yang Y; Hong R; Zhao H; Wei G; Wu W; Xu H; Cui J; Zhang Y; Chang AH; Hu Y; Huang H
    Blood Cancer J; 2020 Oct; 10(10):105. PubMed ID: 33077713
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
    Dias A; Kenderian SJ; Westin GF; Litzow MR
    Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.
    Niu J; Qiu H; Xiang F; Zhu L; Yang J; Huang C; Zhou K; Tong Y; Cai Y; Dong B; Lu Y; Sun X; Wan L; Ding X; Wang H; Song X
    Blood Cancer J; 2023 Mar; 13(1):44. PubMed ID: 36964132
    [No Abstract]   [Full Text] [Related]  

  • 13. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.
    Li HF; Meng WT; Jia YQ; Jiang NG; Zeng TT; Jin YM; Huang QR; Li X; Xu H; Mo XM
    Medicine (Baltimore); 2016 Aug; 95(34):e4128. PubMed ID: 27559941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia.
    Shyr DC; Homsombath AA; Chan PP; Boyer MW; Harris AC
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28155. PubMed ID: 31925900
    [No Abstract]   [Full Text] [Related]  

  • 16. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia].
    Lin ZK; Zhang R; Ge Z; Liu J; Wu YJ; Guo X; Qiao C; Qiu HR; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):289-95. PubMed ID: 23628018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
    Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
    Avanzi MP; Brentjens RJ
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.